Abstract：
Purpose: This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis. Materials and Methods: Residual disease was defined as experiencing moderate, severe, or very severe psoriasis over the past week or having ≥3% body surface area affected, despite treatment. Factors associated with residual disease and its effects on flare-ups, humanistic burden, and health care resource utilization (HCRU) were evaluated. Results: Of the 344 apremilast users (mean age, 44.9 years; female, 65.4%), 174 (50.6%) had residual disease. It was more prevalent in Black versus White participants (OR, 4.5; 95% CI, 1.6-12.2), those receiving apremilast for ≥1 versus <1 year (OR, 16.5; 95% CI, 7.9-34.4), those reporting ≥2 versus 0 to 1 flare-ups during the past 3 months (OR, 10.0; 95% CI, 5.0-20.1), and those with ≥4 versus 1 to 3 body regions affected at time of survey (OR, 8.6; 95% CI, 3.8-19.8). Participants with versus without residual disease self-reported more psoriasis flare-ups over the past 3 months (mean, 4.7 vs 0.9; p < .001) and more anxiety (89.7% vs 50.0%; p < .001) and depression (69.0% vs 23.6%; p < .001) over the past 30 days. Conclusion: Generally, participants with versus without residual disease also had significantly more comorbidities and greater HCRU.
摘要：
目的：这是非干预性的，横断面调查估计了接受apremilast治疗的美国中重度银屑病成人中残留病的患病率和后果.材料和方法：残留疾病被定义为经历中度，严重,或过去一周非常严重的牛皮癣，或有≥3%的体表面积受影响，尽管治疗。与残留病相关的因素及其对突发疾病的影响，人文负担，和卫生保健资源利用(HCRU)进行了评估。结果：在344名apremilast用户中(平均年龄，44.9岁；女性，65.4%），174例（50.6%）有残留病。在黑人和白人参与者中更为普遍(或，4.5；95%CI，1.6-12.2），那些接受apremilast≥1年和<1年的人(OR，16.5；95%CI，7.9-34.4），那些在过去3个月内报告≥2与0至1次突发(OR，10.0；95%CI，5.0-20.1），以及在调查时受影响的身体区域≥4和1至3个(OR，8.6；95%CI，3.8-19.8）。与没有残留疾病的参与者自我报告更多的牛皮癣发作在过去3个月(平均,4.7vs0.9；p<.001）和更多的焦虑（89.7％vs50.0％；p<.001）和抑郁（69.0％vs23.6％；p<.001）。结论：一般来说，有残留疾病的参与者与无残留疾病的参与者相比,合并症明显更多,HCRU也更多.
